Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05340569 | Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.(DWI-PDAC) | completed | N/A | 40 | Laval UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT00545545 | Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 32 | HiberCell, Inc.INDUSTRY | 1 | Mar 19, 2025 |
| NCT04668781 | Improvement of Care of Patients Undergoing Pancreaticoduodenectomy | completed | N/A | 92 | Helsinki University Central HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT05233098 | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | completed | — | 6 | Boston Scientific CorporationINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01939275 | 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | completed | N/A | 8 | City of Hope Medical CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05303090 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 56 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06316882 | Gastric Cancer Endoscopic Screening in an Intermediate-risk Country - ROGCAS, a Dual-centre Pilot Program(ROGCAS) | completed | — | 349 | Unidade Local De Saúde Do Norte AlentejanoOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT06233253 | Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04631445 | Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer | completed | N/A | 32 | Translational Drug DevelopmentOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05010668 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 28 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02907099 | Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03092518 | Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04022746 | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer | completed | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06037343 | Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI | completed | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04306367 | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | completed | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05236699 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC(CCGLC-005) | completed | Phase 2 | 23 | Tongji HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03992664 | Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. | completed | N/A | 40 | Cyprus University of TechnologyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04015804 | Robotic Low Rectum Anterior Resection(GROG-R01) | completed | N/A | 833 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 3 | Feb 12, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02188264 | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT04361331 | Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 61 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05727319 | Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)(AIR-PANC) | completed | — | 13 | NHS Greater Glasgow and ClydeOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05792735 | Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer(NeoCaCRT) | completed | Phase 2 | 27 | Shenzhen People's HospitalOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04732494 | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(AdvanTIG-203) | completed | Phase 2 | 125 | BeiGeneINDUSTRY | 6 | Jan 31, 2025 | clinicaltrials |
| NCT02000050 | Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)(COLORE) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT02089269 | Tumor Registry Pancreatic Cancer(AMETHYST) | completed | — | 2,325 | iOMEDICO AGINDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06720675 | Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence | completed | — | 237 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05431621 | Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers | completed | — | 2,430 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06799182 | Periodontal Disease and Colorectal Cancer(PD and CRC) | completed | N/A | 20 | University Medical Centre LjubljanaOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06799468 | Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation(TRAIN-AI) | completed | — | 1,769 | European Hepatocellular Cancer Liver Transplant GroupOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT04662112 | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma(NASOX) | completed | Phase 1 / Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Mar 20, 2025source: clinicaltrials